DrugApproved
Insulin icodec
insulin icodec
Long-acting insulin analogue injected once a week. US FDA approved it for adults with type 2 diabetes in 2026 and, per FDA notice of 23 October 2026, for children aged 10 and older with type 2 diabetes, based on a single-dose pharmacokinetic study in 18 children and modelling from adult data. Hypoglycaemia is the most common adverse reaction.
Also in the catalogue
- Liu J, Yi T, Xing P, et al. Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion (MILD-MT). N Engl J Med, 2026Publication
- Skoulidis F, Ahn MJ, Gadgeel S, et al. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC (Krascendo 1). N Engl J Med, 2026Publication
- Zolacabtagene autoleucelDrug
- DivarasibDrug
- ЛорундростатDrug
- Мебуфотенин (5-MeO-DMT, BPL-003)Drug
Scales
Identifiers
- INN
- insulin icodec
Details
- Status
- Approved
- Class
- Once-weekly basal insulin analogue
- Trade names
- Awiqli
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.